Title: On Demand Webinar: Exhibitor Seminar: Epredia - Multiplex immunofluorescence IHC is a powerful technique to address increasing research needs in immuno-oncology to better understand tumor environment (exhibitor webinar)
Available On Demand
In this webinar, we will present a rapid, automated, high-plex fluorescent immunostaining procedure using the microfluidic-based staining device, LabSat® Research, and TSA staining reagents. The 6-marker protocol could be performed in less that 4 hours and 30 minutes, resulting in high quality marker detection, efficient removal of antibodies and remarkable signal uniformity. Create a more on-demand workflow by combining rapid immunohistochemistry with digital pathology and reduce your total time by 50-60%, boosting your lab’s efficiency and promoting more consistency in collaborative research.
Join us and experience how these technologies can improve your research activities.
Barbara Cahill is the Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology at Epredia, a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Barbara is an accomplished marketer who has accelerated new product development initiatives in the life sciences and self-care industries for almost 20 years. Her experiences enable her to transform and lead with market disruptive technologies that personally and professionally align with Epredia’s mission and vision to improve lives by enhancing precision cancer diagnostics.
Chris Coley is the Global Marketing Development Manager for Digital Pathology at Epredia, a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Chris has an extensive Anatomical Pathology background followed by various roles in sales and marketing for comprehensive product lines in the both clinical and research segments for over 25 years. His experiences enable him to implement market enhancing technologies that professionally align with Epredia’s mission and vision to improve lives by enhancing precision cancer diagnostics.